Physician profile
Robert L Carter
NPI 1649477191
$2,586.14
in general payments reported to CMS, 2019-2025
24 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $136 · 2021: $69.29 · 2022: $885 · 2023: $955 · 2024: $197 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.00 | 2022-2023 | Vraylar, Qulipta, Ubrelvy |
| Inspire Medical Systems, INC. | $504.67 | 2023-2025 | Inspire |
| Lilly USA, LLC | $240.09 | 2019-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $176.35 | 2020-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $151.76 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.98 | 2021-2023 | Ofev, Jardiance |
| Novo Nordisk INC | $119.80 | 2022-2023 | Saxenda, Wegovy |
| Supernus Pharmaceuticals, INC. | $81.92 | 2022-2023 | Qelbree |
| Pfizer INC. | $75.50 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.69 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $55.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.48 | 2022 | |
| Astellas Pharma US INC | $40.42 | 2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $37.63 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.99 | 2023-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.95 | 2023 | Trulance, Xifaxan |
| Nestle Healthcare Nutrition INC. | $30.15 | 2022-2023 | |
| Amgen INC. | $25.87 | 2022-2023 | Repatha |
| Mylan Specialty L.P. | $24.14 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2022 | |
| Merck Sharp & Dohme LLC | $22.69 | 2022 | |
| Glaxosmithkline, LLC. | $16.07 | 2023 | Shingrix |
| Lundbeck LLC | $15.79 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.